Duration of Anticoagulant Effect in Relation to Urinary Excretion of Dextran Sulphate

Alopecia following Treatment with Dextran Sulphate and Other Anticoagulant Drugs

“…We observed severe alopecia in 8 out of 15 patients who had been followed up for at least three months after receiving 90,000 or more units of dextran sulphate; in three of these cases alopecia was not apparent until two months after the end of treatment. The lower incidence of alopecia reported by some other workers with dextran sulphate may be due partly to smaller dosage (Donzelot et al, 1955) and partly to inadequate follow-up, as it was not at first realized that a latent period of two months might elapse between treatment and loss of hair (Jeavons et al, 1956). The incidence of alopecia is much less when a smaller dose of dextran sulphate is given, and in the present study only 2 out of 12 patients receiving less than 40,000 units of dextran sulphate, along with a coumarin anticoagulant, developed mild alopecia.…”

“…May (1951) reported transient alopecia in 70% of patients treated with " thrombocid." Dextran sulphate treatment has been previously reported to be followed by alopecia in 10% of cases (Donzelot et al, 1955;Jeavons et al, 1956). Using a higher dosage than most other workers, Hjort and Stormorken (1957) found that all 10 patients who received 20,000 units of dextran sulphate daily for 10 days suffered loss of hair.…”

“…It differs from heparin in its more prolonged anticoagulant and greater cumulative effects (Ricketts et al, 1953;Donzelot et al, 1955;Jeavons et al, 1956;Cohen and Tudhope, 1956). The commonest toxic effect of dextran sulphate is transient alopecia, which has been described in about 10% of cases (Donzelot et al, 1955;Jeavons et al, 1956), but the frequency of this complication has probably been underestimated, because it may not appear until several weeks after treatment has been stopped. Hjort and Stormorken (1957) have described 10 cases treated with high dosage of dextran sulphate in which loss of hair developed 8 to 10 weeks later.…”

Reduction of low‐density lipoproteins with dextran sulfate in patients with familial hypercholesterolemia

“…Some of the untoward reactions seen in our patients, such as posttreatment leukocytosis, flushing, fatigue, headache, hives, hypotension, low back pain, and nasal congestion, appeared to be due to complement activation, since they were lessened when complement activation was reduced by elimination of Mg++ from the precipitation solution. A rise in hepatic enzymes or gastrointestinal discomfort may have been caused by DxS, since it is known to be excreted in both bile [16] and urine [17], as well as metabolized in the liver [HI. In addition to thrombocytopenia, alopecia and arthralgia have been the most prominent side effects seen by other investigators during the administration of DxS to humans 1191.…”

The Estimation and Recovery of Dextran Sulphates in Biological Fluids

“…It was necessary to make accurate dilutions of an unknown solution to ensure that values obtained fell upon this linear portion of the curve relating percentage of dye bound to the dextran sulphate concentration. This method has been found useful, for example, in estimating the excretion of dextran sulphates in the urine of experimental animals (Ricketts, Walton, and Saddington, 1954) and in man (Jeavons, Walton, and Ricketts, 1956) where the small amounts of protein normally present are insufficient to interfere with the production of metachromasia.…”